A new DPI device for the generic drugs market

MRX003: a capsule dry powder inhaler
MRX003: a capsule dry powder inhaler

MERXIN and Gerresheimer worked successful together to realize the shortest possible time to market for the MERXIN MRX003 Capsule DPI

Wackersdorf, June 13, 2022: Gerresheimer has assumed responsibility for the industrialization of a dry powder inhaler for the treatment of respiratory ailments for MERXIN (United Kingdom), a company that specializes in making inhaler devices. The inhaler is produced in Pfreimd (Germany) for worldwide distribution. Beyond the technically sophisticated industrialization of the product, the main challenge of the project was to coordinate an optimal development process aimed at ensuring the shortest possible time to market at the lowest cost.

MERXIN MRX003 capsule dry powder inhaler is used for pulmonary delivery and in particular for the treatment of chronic, obstructive pulmonary diseases (COPD) and asthma. The API is aerosolized and distributed with the respiratory system to find its way deep into the lungs of the patient. The correct interplay of inhaler and formulation plays a decisive role in the success of the treatment.

The first product target for MRX003 was a generic version of an API. Because of the nature of the generic market, it was of essential to achieve the shortest possible time to launch. This was achieved through a close cooperation between the partners. Decades of expertise and know-how in inhaler design and production were combined between Gerresheimer and MERXIN. Jochen Wegerer (Program Manager, Gerresheimer Regensburg GmbH, Wackersdorf) was impressed by the cooperation: “The good teamwork within the project is noteworthy. Challenges were always discussed in a goal-oriented, creative, and open manner, so that approaches to solutions could be formulated and implemented within the shortest time possible.”

The design of the manufacturing process of MRX003, had to deliver high product quality with the most stable, fully automated processes possible and to enable affordable production for the generic drugs market. “With the help of our DMF package, we were able to create, implement, and qualify the molds to be very robust,” Richard Gradl (Mold Engineer, Gerresheimer Regensburg GmbH, Wackersdorf) explains. “The stable component quality and high process capability of the molds ensure good conditions in the series production environment.” Our risk management approach was based on procedures that were tailored to the special features of the project, from qualification and validation to long-term production security, as highlighted by Tobias Bernklau (Global Head of Quality Engineering, Gerresheimer Regensburg GmbH, Wackersdorf): “The focus is always on the user for all decisions. For critical areas and functions, we deliberately invest more effort than for less critical areas and functions.”

MRX003 is assembled from a total of 12 parts, meaning seven injection molding parts of ABS or MABS (base element, capsule housing, hinge plate, button, mouthpiece, filter housing, sealing cap) as well as five stainless steel bought-in components (two lancets, spring, cylinder pin, and fine filter unit). A pouch is used for the packaging of the finished product. For the BICs, Gerresheimer selected suppliers who are capable of fulfilling sophisticated quality. The injection molding parts are produced at the Gerresheimer location in Pfreimd in multi-cavity tools. The fully automated assembly and gap-free testing of each individual inhaler takes place at three round table stations.



About Gerresheimer

Gerresheimer is the global partner for pharmaceutics, biotech, healthcare, and cosmetics with a very broad product range for pharmaceutical and cosmetic packaging solutions and drug delivery systems. The company is an innovative solution provider from concept to delivery of the end product. Gerresheimer achieves its ambitious goals through a high level of innovative strength, industrial competence and concentration on quality and customer focus. In developing innovative and sustainable solutions, Gerresheimer relies on a comprehensive international network with numerous innovation and production centers in Europe, America and Asia. Gerresheimer produces close to its customers worldwide with around 10,000 employees and generated annual revenues in 2021 of around EUR 1.5b. With its products and solutions, Gerresheimer plays an essential role in people's health and well-being.

About Merxin Ltd

Merxin designs and supplies generic and customized inhaler device platforms. Our devices include multidose dry powder inhalers, capsule dry powder inhalers, soft mist inhalers, and devices tailored to cannabinoid delivery to the lungs. We create, develop, and supply device platforms for evaluation through to commercial supply. Established in the UK in 2015 and based in King’s Lynn, Merxin maintains manufacturing capacity across the globe, serves an international client base, and is certified as meeting the requirements of ISO 13485:2016 for the Design, Development and Supply of inhalers.
We Make Inhalers.
Who Will Launch You?
For more information, visit www.merxin.com.

Press contact:
Marion Stolzenwald
Gerresheimer AG
Klaus-Bungert-Str. 4
40468 Düsseldorf
Phone: 0211-6181246
E-Mail: marion.stolzenwald-remove@remove-gerresheimer.com

Karin Fischer
Gerresheimer Regensburg GmbH
Oskar-von-Miller-Str. 6
92442 Wackersdorf
Phone_ 09431-639 6140
E-Mail: karin.fischer-remove@remove-gerresheimer.com



邮箱: info-china
电话:186 6119 5281 (微信同号)